N/A N=41 Transcend Auto vs Commercially Available Device Clinical Evaluation for Treatment of Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea
Primary: Mean Apnea Hypopnea Index (AHI) During Treatment — 2.1; 2.0 AHI — p=.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,606 Emergency Medicine Palliative Care Access
Advanced Cancer · End Stage Organ Failure
Primary: Change in Quality of Life for Patients, as Measured by the Functional Assessment of Cancer Therapy - General (FACT-G) — 3.7; 3.1 score on a scale
N/A N=126 Study to Evaluate the Safety and Effectiveness of REAL INTELLIGENCE™ CORI™ in Knee Arthroplasty Procedures
Arthroplasty · Replacement · Knee
Primary: Post-Operative Leg Alignment — 42; 55; 97 Participants
N/A N=225 Autonomous Telephone Follow-up After Cataract Surgery
Cataract · After Cataract
Primary: Agreement — 117; 131; 78; 64 Participants
Phase 2 N=643 HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis
End Stage Renal Disease · Chronic Pain · Opioid Dependence
Primary: Pain Interference — 6.26; 6.45; 5.09; 5.75 score on a scale
Phase 3 N=1,059 Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)
Warts, Genital · Neoplasms, Anal
Primary: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection — 0.2; 2.2 Cases per 100 Person-years — p=<0.001
N/A N=43 Intermittent Catheterisation on the Bladder Mucosa of Healthy Volunteers With a Prototype Micro Hole Zone Catheter
Urinary Incontinence
Primary: Change in Appearance of the Bladder Mucosa (∆=Pre-catheterisation at Baseline and Post-catheterization and Visit 2) Rated on a 4-point Scale. — 0.84; 0.76 score on a scale
N/A N=183 Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx
Non-melanoma Skin Cancer
Primary: Local Recurrence — 2 Lesions
N/A N=46 Effects of a Mobile Application RA Joint Protection and Activity Self-management Program
Arthritis, Rheumatoid
Primary: Self-management Behaviors — 13.24; 14.76 score on a scale
Phase 1 N=28 A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib — 48800; 49700 hour*nanogram per…
Phase 2 N=36 A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B — 1; 0; 0; 2 Participants
Phase 2 N=10 Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device
Ocular Surface Disease
Primary: Ocular Surface Disease Index (OSDI) Score Change (1 Month Post Treatment Initiation) — -3.83 score on a scale
Phase 2 N=41 Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019) · Hypoxia
Primary: Measuring the Change in Inflammation — 23.23; 34.82 mg/L — p=0.01
Phase 1 N=17 A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
Moderate Hepatic Impairment
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan — 22500; 14800 ng*hr/mL
N/A N=190 A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal
Gingivitis · Dental Plaque
Primary: Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 12 — -4.3 bleeding sites — p=0.0032